Standout Papers
Citation Impact
Citing Papers
Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study
2008
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin
2013
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
2016 Standout
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
2013 Standout
Parenteral Anticoagulants
2008
Hallmarks of Cancer: The Next Generation
2011 Standout
Nonheparin Anticoagulants for Heparin-Induced Thrombocytopenia
2013
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
Parenteral Anticoagulants
2012 Standout
Long-Term Engraftment and Fetal Globin Induction upon BCL11A Gene Editing in Bone-Marrow-Derived CD34 + Hematopoietic Stem and Progenitor Cells
2017
No accumulation of the peak anti‐factor Xa activity of tinzaparin in elderly patients with moderate‐to‐severe renal impairment: the IRIS substudy
2011
Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature
2008
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
Mechanisms of Thrombus Formation
2008 Standout
Aberrant β-Catenin Signaling in Tuberous Sclerosis
2005
Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis
2012
Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry
2008
Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep® in Renal Insufficiency Study (IRIS)
2011
The Tuberous Sclerosis Complex
2006 Standout
Approach to the Diagnosis and Management of Drug-Induced Immune Thrombocytopenia
2013
Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency
2009
Evidence-Based Management of Anticoagulant Therapy
2012
Prophylaxis Against Deep Vein Thrombosis in Critically Ill Patients With Severe Renal Insufficiency With the Low-Molecular-Weight Heparin Dalteparin<subtitle>An Assessment of Safety and Pharmacodynamics: The DIRECT Study</subtitle>
2008
Mesoporous silica nanoparticles in biomedical applications
2012 StandoutNobel
New oral antithrombotics: a need for laboratory monitoring. For
2010
Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis
2011
Perioperative Management of Antithrombotic Therapy
2012 Standout
Oral Anticoagulant Therapy
2012 Standout
Prophylaxis for Thromboembolism in Hospitalized Medical Patients
2007
Lung Cancer
2008 Standout
New Antithrombotic Drugs
2012
Risk of Recurrence After a First Episode of Symptomatic Venous Thromboembolism Provoked by a Transient Risk Factor
2010
Antithrombotic Therapy for VTE Disease
2016 Standout
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient‐level meta‐analysis
2010
Severe Sepsis and Septic Shock
2013 Standout
Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry
2014
Colorectal cancer
2019 Standout
Sickle Cell Disease
2017
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads
2012
Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs
2010
A randomized, double‐blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non‐surgical patients: CERTIFY Study
2010
Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study
2014
Fondaparinux for Isolated Superficial Vein Thrombosis of the Legs
2011
Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials
2011
Executive Summary
2012 Standout
The Missing Diversity in Human Genetic Studies
2019 Standout
Prevalence and specificity of LKB1 genetic alterations in lung cancers
2007
Prevention of VTE in Nonorthopedic Surgical Patients
2012 Standout
Systemic Lupus Erythematosus
2011 Standout
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke
2012
Fluorescent Nanorods and Nanospheres for Real‐Time In Vivo Probing of Nanoparticle Shape‐Dependent Tumor Penetration
2011 StandoutNobel
Autoimmune heparin‐induced thrombocytopenia
2017
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
Medical literature, vena cava filters and evidence of efficacy
2013
Prevention of Venous Thromboembolism
2004 Standout
Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature
2007
LKB1; linking cell structure and tumor suppression
2008
PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma
2010
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis
2011
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study
2009
Prevention of Venous Thromboembolism
2008 Standout
Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility
2010
An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN
2010
Antithrombotic Therapy in Neonates and Children
2008
Pancreatic Cancer
2010 Standout
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2009 Standout
Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation
2010
Pyrene-labeled lipids as tools in membrane biophysics and cell biology
2002
Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients
2009
TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth
2006 Standout
Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management
2007
Basic mechanisms and pathogenesis of venous thrombosis
2009
Immune thrombocytopenic purpura in adults
2007
Antiphospholipid syndrome
2010
Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE)
2007
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
2013 Standout
Troponin elevation in coronary vs. non-coronary disease
2010
Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia
2016
Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines
2012
ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes
2015
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
2012
Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism
2010
Extracellular DNA traps promote thrombosis
2010 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
2017 Standout
Photoexpulsion of Surface-Grafted Ruthenium Complexes and Subsequent Release of Cytotoxic Cargos to Cancer Cells from Mesoporous Silica Nanoparticles
2013 StandoutNobel
Antithrombotic Therapy in Patients With Chronic Kidney Disease
2012
Current Options for the Treatment of Idiopathic Thrombocytopenic Purpura
2007
One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA
2021 StandoutNobel
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment Strategies
2014
Fluorescence Lifetime Measurements and Biological Imaging
2010 Standout
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
2008 Standout
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism
2012
Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function
2007
Plasmons in Strongly Coupled Metallic Nanostructures
2011 Standout
Diagnosis and Management of Cerebral Venous Thrombosis
2011 Standout
Prevention of Venous Thromboembolism in Hospitalized Patients With Cancer
2009
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform
2011 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
2021 Standout
Patient-Level Meta-analysis: Effect of Measurement Timing, Threshold, and Patient Age on Ability of d -Dimer Testing to Assess Recurrence Risk After Unprovoked Venous Thromboembolism
2010
Metal–Organic Frameworks in Biomedicine
2011 Standout
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non–ST-Segment Elevation Acute Coronary Syndromes
2007
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2013
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
2021 Standout
Prevention of deep vein thrombosis and pulmonary embolism
2015
Prediction of venous thromboembolism in cancer patients
2010
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
2021 Standout
Works of Wendy Lim being referenced
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
2011 Standout
Sequence changes in predicted promoter elements of STK11/LKB1 are unlikely to contribute to Peutz-Jeghers syndrome
2005
Inherited thrombophilia and pregnancy associated venous thromboembolism
2007
The Frequency and Clinical Significance of Thrombocytopenia Complicating Critical Illness
2010
Low molecular weight heparin and bleeding in patients with chronic renal failure
2007
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment
2009
Prevention of VTE in Nonsurgical Patients
2012 Standout
Relative frequency and morphology of cancers in STK11 mutation carriers1 ☆
2004
Low-molecular-weight heparin in patients with chronic renal insufficiency
2008
Safety and Efficacy of Low Molecular Weight Heparins for Hemodialysis in Patients with End-Stage Renal Failure
2004
Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis
2008
Management of Antiphospholipid Antibody Syndrome
2006
Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura
2007
Can heparin‐induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal
2008
Elevated Cardiac Troponin Measurements in Critically Ill Patients
2006
Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency
2006
Periprocedural Heparin Bridging in Patients Receiving Vitamin K Antagonists
2012
The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis
2014
Update on the use of hydroxyurea therapy in sickle cell disease
2014
Mechanism of liposome destabilization by polycationic amino acids
1995
Systematic Review: d -Dimer to Predict Recurrent Disease after Stopping Anticoagulant Therapy for Unprovoked Venous Thromboembolism
2008
Meta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical Patients
2007